371P - Male breast cancer: the experience of an oncological center

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Breast Cancer, Metastatic
Presenter Miguel Abreu
Authors M.H. Abreu1, E. Matos2, N. Afonso1, D. Pereira1, H. Rodrigues3, R. Henrique4, C. Lopes5
  • 1Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 - Porto/PT
  • 2Health Community, Biomedical Sciences Institute of Abel Salazar, University of Porto, Porto/PT
  • 3Medical Oncology/ Hematology, Portuguese Oncology Institute of Porto, 4200-072 - Porto/PT
  • 4Pathology, Portuguese Oncology Institute of Porto, Porto/PT
  • 5Pathology, Biomedical Sciences Institute of Abel Salazar, University of Porto, Porto/PT



Male Breast Cancer (MBC) is a rare condition comparing to Female Breast Cancer (FBC). Because of that, its understanding is weak and its treatment has often been extrapolated from FBC in spite of many important differences already suggested by many studies. Objective: To evaluate risk factors, recurrence and survival in male breast cancer.

Material and methods

Review of clinical files of 115 male patients diagnosed with breast cancer and treated in the IPO- Porto from 1976 to 2011. Evaluation of demographic, tumor- related variables, treatment and survival were done. Survival curves were calculated by the Kaplan-Meier method and compared using the log-rank test. Statistical significance was set at p < 0.05.


The median age of the treated patients was 63 years-old (33-94 years-old). Prior or active tobacco use was observed in 36,1% and alcohol use 44,8%. Over-weight or obesity was registered in 66,7% of the cases. 48,8% of the patients reported a positive family history of cancer (17,4% of breast or ovarian cancer in a first-degree member), 8,3% were BRCA2 positive and 12,5% developed secondary malignancies. Most tumors were located in left breast (55,7%), were ductal carcinomas (91,2%), G2 (54,6%), stage III (46,4%) or II (26,8%), with positive hormonal receptors (90,4%) and with limphovascular invasion (67,4%). The majority of patients underwent surgery (95,6%), followed by chemotherapy, radiotherapy and hormonotherapy (26,1%) or radiotherapy and hormonotherapy (26,1%). 32,4% relapsed, in visceral non-hepatic sites (32,4%) or hepatic (17,6%). Median recurrence-free survival was 27,3% at five years. 5-years cancer- specific survival was 71,3%. In univariate analysis were prognostic factors the advanced stage (p < 0,001) and hepatic recurrence versus other sites (p = 0,014). The last factor was the only independent prognostic factor. 33,9% of the patients died for breast cancer.


This study confirmed many differences between MBC and FBC namely: older age at diagnose, high prevalence of family history, BRCA2 mutations and second malignancies. Cancer-specific survival is similar when adjusted to other factors such as stage and local of recurrence.


All authors have declared no conflicts of interest.